NASDAQ · IFRX
InflaRx N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IFRX: Nov 9, 2026
InflaRx N.V. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.07. The reported EPS for the same quarter last year was $-0.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.07 | $-0.06 | $-0.09 | 3 |
| Dec 2026 | $-0.07 | $-0.06 | $-0.09 | 3 |
| Mar 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Jun 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · MarketBeat · RTTNews- Fintel · Oct 22, 5:24 PM EDTInflaRx N.V. Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026InflaRx N.V. announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses an
- Fintel · Sep 14, 1:43 PM EDTNeedham Initiates Coverage of InflaRx N.V. with Buy RatingFintel reports that on September 14, 2026, Needham initiated coverage of InflaRx N.V. (NASDAQGS:IFRX) with a Buy recommendation.InflaRx N.V., based in Jena, Germany, operates in the biopharmaceutical domain, primarily focusing on the development of innovative therapies for inflam
- Zacks · Aug 4, 8:50 AM EDTCertara, Inc. (CERT) Q2 Earnings and Revenues Lag EstimatesCertara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 26, 5:16 AM EDTStrength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Fintel · May 13, 8:04 PM EDTRaymond James Upgrades InflaRx N.V. (IFRX)Fintel reports that on May 13, 2026, Raymond James upgraded their outlook for InflaRx N.V. (NasdaqGS:IFRX) from Outperform to Strong Buy. Analyst Price Forecast Suggests 245.57% Upside
- MarketBeat · May 8, 11:53 AM EDTInflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease PipelineInflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Izicopan positioned as
- Zacks · Mar 19, 8:45 AM EDTInflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue EstimatesInflaRx (IFRX) delivered earnings and revenue surprises of +2.86% and -117.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Mar 16, 2:39 AM EDTInflaRx Receives Nasdaq Minimum Bid Price Notice(RTTNews) – InflaRx N.V., a clinical-stage biopharmaceutical company (IFRX), announced that it has received a notice from Nasdaq indicating non-compliance with the minimum bid price and listing rules.
- RTTNews · Jan 2, 6:37 AM ESTWeekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX?(RTTNews) – Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and strategic buyouts.
- RTTNews · Dec 30, 10:46 AM ESTInflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum(RTTNews) – InflaRx N.V. (IFRX) today released detailed analyses from its terminated Phase 3 trial of Vilobelimab in pyoderma gangrenosum. The study was stopped in May 2025 after an Independent Data Monitoring Committee (IDMC) recommended discontinuation for futility, and subsequ
- RTTNews · Dec 30, 9:23 AM ESTInflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market(RTTNews) – InflaRx N.V. (IFRX), Tuesday announced updates regarding its Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this year after an Independent Data Monitoring Committee recommended the trial be stopped early due to futility.
- Fintel · Nov 16, 7:18 PM ESTInflaRx N.V. (IFRX) Price Target Increased by 179.31% to 11.80The average one-year price target for InflaRx N.V. (NasdaqGS:IFRX) has been revised to $11.80 / share. This is an increase of 179.31% from the prior estimate of $4.23 dated November 7, 2025. The price target is an average of many targets provided by analysts.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for InflaRx N.V. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.